IIT: Pilot Phase Ib/II Study of Durvalumab (MEDI4736) and Chemoradiation for Esophageal and Gastroesophageal Junction Adenocarcinoma
The purpose of this study is to assess the safety of adding the investigational drug durvalumab (also called MEDI4736) to chemoradiation using two standard chemotherapy drugs, carboplatin and paclitaxel, before surgery in patients with cancers of the esophagus or the junction between the esophagus and stomach (gastroesophageal junction). The medications used in this study are given intravenously (by vein).
To be eligible for this study, patients must:
- Have operable esophageal or gastroesophageal cancer.
- Have not had prior chemotherapy.
- Have an ECOG status of 0 or 1.
- Be age 18 or older.
For more information about this study and to inquire about eligibility, please contact Dr. Geoffrey Ku at 646-888-4588.